Compare Stocks

Star Diamond Corporation engages in the exploration, development, and production of diamonds in Canada. The company's principal mineral properties include the Star Kimberlite property and the Orion South Kimberlite property located in Fort à la Corne area of Saskatchewan, Canada. It also holds a 50% interest in the Buffalo Hills project located in north central Alberta, Canada. The company was formerly known as Shore Gold Inc. and changed its name to Star Diamond Corporation in February 2018. The company was incorporated in 1985 and is headquartered in Saskatoon, Canada.

EMX Royalty Corporation, together with its subsidiaries, explores for and generates royalties from metals and minerals properties. It explores for gold, silver, platinum, palladium, copper, lead, zinc, nickel, cobalt, volcanogenic massive sulfide, molybdenum, and iron deposits. The company's royalty and exploration portfolio primarily consist of properties in North America, Turkey, Europe, Australia, and Latin America. The company was formerly known as Eurasian Minerals Inc. and changed its name to EMX Royalty Corporation in July 2017. EMX Royalty Corporation is headquartered in Vancouver, Canada.

MFS Intermediate Income Trust is a closed ended fixed income mutual fund launched and managed by Massachusetts Financial Services Company. The fund invests in fixed income markets across the globe. It primarily invests in debt instruments. The fund seeks to benchmarks the performance of its portfolio against the Barclays Intermediate U.S. Government/Credit and MFS Intermediate Income Trust Blended Index. MFS Intermediate Income Trust was formed on March 17, 1988 and is domiciled in the United States.

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.